Biosceptre meet with NSW Health Minister, Ryan Park
It was a privilege for Biosceptre CEO, Gavin Currie and [...]
Biosceptre secures £7m. to boost novel CAR T therapy
Biosceptre today announced the securing of £7m. (US$9.6m.) in funds [...]
Biosceptre appoints new Chief Scientific Officer
Cambridge, UK, 20 October 2014. Biosceptre, the oncology company developing antibody products
Biosceptre publishes preclinical data on nf-P2X7 in the Journal of Clinical and Cellular Immunology
Paper concludes Biosceptre's target nf-P2X7 is ubiquitous to all cancer [...]
Biosceptre secures Technology Strategy Board Award
Award to develop new therapeutic antibodies targeting nf-P2X7 to treat cancer [...]
Biosceptre moves corporate headquarters to the UK from Australia
Move provides greater access to investors, grants, partners and expertise [...]